Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 257

    1.

    Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

    Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM.

    Arthritis Res. 2001;3(3):178-82. Epub 2001 Feb 19.

    PMID:
    11299058
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.

    Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW.

    Clin Exp Rheumatol. 2001 Jan-Feb;19(1):69-74.

    PMID:
    11247328
    [PubMed - indexed for MEDLINE]
    3.

    Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.

    La Montagna G, D'Angelo S, Valentini G.

    J Rheumatol. 2003 Oct;30(10):2147-51.

    PMID:
    14528508
    [PubMed - indexed for MEDLINE]
    4.

    Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.

    Zachariae H, Heickendorff L, Bjerring P, Halkier-Sørensen L, Søndergaard K.

    Acta Derm Venereol. 1994 Sep;74(5):368-70.

    PMID:
    7817674
    [PubMed - indexed for MEDLINE]
    5.

    Bioactivity of prolactin in systemic sclerosis.

    La Montagna G, Meli R, Criscuolo T, D'Angelo S, Valentini G.

    Clin Exp Rheumatol. 2004 Mar-Apr;22(2):145-50.

    PMID:
    15083880
    [PubMed - indexed for MEDLINE]
    6.

    Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).

    Zachariae H, Bjerring P, Halkier-Sørensen L, Heickendorff L, Søndergaard K.

    Acta Derm Venereol. 1994 Nov;74(6):444-6.

    PMID:
    7701875
    [PubMed - indexed for MEDLINE]
    7.

    von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII).

    Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J.

    Thromb Haemost. 1998 Dec;80(6):1002-7.

    PMID:
    9869174
    [PubMed - indexed for MEDLINE]
    8.

    von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.

    Nossent AY, VAN Marion V, VAN Tilburg NH, Rosendaal FR, Bertina RM, VAN Mourik JA, Eikenboom HC.

    J Thromb Haemost. 2006 Dec;4(12):2556-62. Epub 2006 Oct 16.

    PMID:
    17059421
    [PubMed - indexed for MEDLINE]
    9.

    Antiendothelial cell antibodies: useful markers of systemic sclerosis.

    Salojin KV, Le Tonquèze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, Youinou PY.

    Am J Med. 1997 Feb;102(2):178-85.

    PMID:
    9217568
    [PubMed - indexed for MEDLINE]
    10.

    Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.

    van Genderen PJ, Boertjes RC, van Mourik JA.

    Thromb Haemost. 1998 Sep;80(3):495-8.

    PMID:
    9759633
    [PubMed - indexed for MEDLINE]
    11.

    Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.

    Nagy Z, Czirják L.

    Clin Exp Rheumatol. 2005 Mar-Apr;23(2):165-72.

    PMID:
    15895885
    [PubMed - indexed for MEDLINE]
    12.

    Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

    Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.

    Blood. 2008 May 15;111(10):4979-85. Epub 2008 Mar 14.

    PMID:
    18344424
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

    Matucci-Cerinic M, Giacomelli R, Pignone A, Cagnoni ML, Generini S, Casale R, Cipriani P, Del Rosso A, Tirassa P, Konttinen YT, Kahaleh BM, Fan PS, Paoletti M, Marchesi C, Cagnoni M, Aloe L.

    Ann Rheum Dis. 2001 May;60(5):487-94.

    PMID:
    11302871
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?

    Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM.

    J Rheumatol. 1994 Oct;21(10):1838-44.

    PMID:
    7837147
    [PubMed - indexed for MEDLINE]
    15.

    Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis.

    Scheja A, Eskilsson J, Akesson A, Wollheim FA.

    J Rheumatol. 1994 Apr;21(4):639-42.

    PMID:
    8035386
    [PubMed - indexed for MEDLINE]
    16.

    Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.

    Zachariae H, Halkier-Sørensen L, Heickendorff L.

    Acta Derm Venereol. 1989;69(1):66-70.

    PMID:
    2563612
    [PubMed - indexed for MEDLINE]
    17.

    Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.

    Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L.

    Clin Exp Rheumatol. 2008 May-Jun;26(3):414-20.

    PMID:
    18578962
    [PubMed - indexed for MEDLINE]
    18.

    Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.

    Kikuchi K, Ihn H, Sato S, Igarashi A, Soma Y, Ishibashi Y, Takehara K.

    Arch Dermatol Res. 1994;286(2):77-80.

    PMID:
    8154928
    [PubMed - indexed for MEDLINE]
    19.

    Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.

    Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T.

    Rheumatology (Oxford). 2000 Oct;39(10):1110-3.

    PMID:
    11035131
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

    Kahaleh MB, Osborn I, LeRoy EC.

    Ann Intern Med. 1981 Apr;94(4 pt 1):482-4.

    PMID:
    6782927
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk